key inclusion criteria: 1. subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. 2. subjects who are or will be inpatient. key

key inclusion criteria: 1. subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. 2. subjects who are or will be inpatient. key

key inclusion criteria: subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. subjects who are or will be inpatient. key

key inclusion criteria: subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. subjects who are or will be inpatient. key

key inclusion criteria: 1. subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. 2. subjects who are or will be inpatient. key

key inclusion criteria: 1. subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. 2. subjects who are or will be inpatient. key